OBJECTIVES: Transcatheter aortic valve replacement (TAVR) and minimally invasive aortic valve replacement (MIAVR) have emerged as alternatives to surgical aortic valve replacement (SAVR) via traditional sternotomy. However, their effect on clinical practice remains unclear. The study's objective is to describe clinical trends between TAVR, MIAVR and SAVR in patients with severe aortic stenosis (AS).
INTRODUCTION
There are few diseases as deadly as severe aortic stenosis (AS). Patients with severe inoperable AS have a 3% 5-year survival rate, lower than survival of many lethal cancers [1] . With survival rates as low as 50% at 2 years and 20% at 5 years after symptom onset, new therapeutic strategies have emerged over the past few decades to address this important disease [2] . Balloon valvotomy in the 1980s ushered in a wave of optimism for AS treatment but did not provide long-term efficacy. As the 21st century approached, surgical aortic valve replacement (SAVR) via full sternotomy became the gold standard to treat severe AS. While SAVR has proven to be a highly successful therapy, it confers select disadvantages in high-risk patients, including those with prior cardiac surgery, renal dysfunction or advanced age.
Aortic valve replacement (AVR) therapy was later refined with the introduction of minimally invasive aortic valve replacement (MIAVR) and transcatheter aortic valve replacement (TAVR), to accommodate patients who were not ideal candidates for SAVR. Several trials showed MIAVR and TAVR to be safe and viable options for high-risk subgroups of patient populations, including those with an advanced age and poor left ventricular function with severe AS [3] . Improved device technology and surgeon technique coupled with increased patient demand for less invasive therapies have pushed some physicians to recommend TAVR and MIAVR over SAVR [4] . Despite the exponential growth of minimally invasive therapies in the last decade, the clinical impact and trends of these technologies remains unclear.
The objective of this study is to describe clinical trends between TAVR, MIAVR and SAVR in a multi-institutional cohort of 2571 patients with severe AS. No study to date has compared SAVR, MIAVR and TAVR, including transapical (TA) and transfemoral (TF) approaches in a large, multi-institutional cohort.
PATIENTS AND METHODS
A multi-institutional retrospective review of 2571 patients undergoing SAVR (n = 842), MIAVR via right anterior thoracotomy (n = 699), and TAVR (n = 1030) from 2011 to 2014 was performed from three centres with equal experience in TAVR, MIAVR and SAVR (Emory University, Atlanta, Georgia; Mount Sinai Hospital, Miami, Florida; University of Texas -Memorial Hermann, Houston, Texas). All patients with severe AS who underwent AVR were included in the study; no patients were excluded. The predominate MIAVR approach was via a right anterior thoracotomy. TAVR patients were further stratified as either TF (n = 727) or TA (n = 303) approaches. Caseload for each procedure was risk stratified by procedure year, STS score (<4%, 4-8%, >8%), age (<80 and > _80), left ventricle ejection fraction (EF) (<40 and > _40), body mass index (BMI) (<30 and > _30), redo-AVR, and patients receiving dialysis. This sample of patients were included in the institution's Society for Thoracic Surgeons (STS) Adult Cardiac Database. Individual patients were not identified, and consent was waived. This study was HIPAA-compliant, and was approved by the Institutional Review Board.
Percent changes were calculated as the change of case volume from 2011 to 2014 divided by the case volume in 2011. Expressed as a single equation, is 100%Â(Volume2014 -Volume2011)/Volume2011. Figures were generated using Microsoft Excel (Microsoft, Redmond, WA, USA) and graph lines were smoothed by Spline interpolation.
RESULTS

Volume
A total of 2571 patients underwent isolated AVR via SAVR (N = 842), TF (N = 727), TA (N = 303) and MIAVR (N = 699) from 2011 to 2014 (Fig. 1) . Table 1 shows AVR volume stratified by procedure type and by year (Table 1) . Total AVR caseload grew +107%. TF (+595%) experienced the largest growth over 4 years, although TA (+177%), MIAVR (+57%) and SAVR (+23%) also saw significant increases. Interestingly, TA (-49%) and SAVR (-15%) sharply decreased from 2013 to 2014.
STS score
When stratified by STS score, MIAVR and SAVR was used predominately for low-risk (STS <4%) patients while TF was preferred for high-risk (STS >8%) patients (Fig. 2) . Intermediate risk (STS 4-8%) patients mainly underwent MIAVR, SAVR and TF. Low-risk patients underwent MIAVR and SAVR almost exclusively, although MIAVR steadily increased (+43%) over 4 years while SAVR experienced a decline (-8%) from 2013 to 2014. SAVR accounted for 53% of total 4-year case volume for intermediate risk patients but underwent a decrease (-15%) from 2012 to 2014. Additionally, MIAVR (+275%) and TF (+1350%) steadily increased over the 4-year period. High-risk patients mainly underwent TF (40%) and SAVR (38%) overall, although TF (+6300%) experienced exponential growth while SAVR (-14%) declined. Both SAVR and TA steadily increased until 2013 where they sharply decreased (-50% and -37%, respectively).
Age
Patients <80 years more commonly underwent SAVR (44%) and MIAVR (31%), while those > _80 years underwent TF (45%). Interestingly, TF experienced the largest overall increases in both categories (age <80: +1657%, age > _ 80: +376%) despite accounting for only 17% of cases for patients less than 80 years (Fig. 3) . SAVR had the smallest increase (+34%) of all 4 procedures for age <80 years, and actually declined (-37%) for age > _80 years. TA grew +622% from 2011 to 2013 for age <80 years before it decreased (-43%) from 2013 to 2014.
Redo aortic valve replacement operations
TF (42%) and SAVR (28%) more frequently favoured than TA (20%) and MIAVR (9%) overall for redo operations (Fig. 4) . While SAVR accounted for the second largest share of overall redo caseload, it increased (+9%) slightly while TF (+500%), MIAVR (436%) and TA (200%) greatly increased. Similar to other study variables, TA (-48%) and SAVR (-18%) underwent sharp declines from 2013 to 2014. Dialysis SAVR (48%) accounted for the most overall cases for patients on dialysis compared to TF (27%), MIAVR (13%) and TA (12%). TF had the greatest growth for dialysis patients, going from zero cases in 2011 to the majority of cases (39%) in 2014 (Fig. 4) . Additionally, SAVR declined (-25%) in the final year while TF (+120%), MIAVR (+33%) and TA (+33%) increased.
Ejection fraction
In patients with an EF < 40, TF took the majority share (40%) of total caseload and also saw the largest overall growth (+556%). SAVR (31%) made up the second largest share of total caseload, followed by TA (16%) and MIAVR (14%). TA (+150%) and MIAVR (+29%) experienced overall increases with SAVR (-4%) slightly decreasing over time (Fig. 5) . From 2013 to 2014, MIAVR (+64%) and TF (+34%) increased sharply while SAVR (-13%) and TA (-13%) decreased equally. Total caseload for patients with EF > _ 40 had relatively similar volumes between SAVR (33%), MIAVR (30%) and TF (26%), while TA had the smallest share (11%). TF (+594%) experienced the greatest overall growth for EF > _ 40, with more modest increases in TA (+200%), MIAVR (+59%) and SAVR (+29%). Additionally, SAVR (-15%) and TA (-56%) decreased from 2013 to 2014 while TF (+27%) and MIAVR (+24%) had similar growth.
Body mass index (BMI)
Caseloads for patients with BMI > _ 30 ( 
30-Day mortality
From 2011 through 2014, overall incidence of 30-day mortality ( Fig. 7 ) was highest for TA-TAVR (5.0%), followed by TF-TAVR (1.9%), SAVR (1.8%) and MIAVR (0.6%).
Stroke TF-TAVR (2.2%) and SAVR (2.1%) had the largest overall incidence of stroke, while TA-TAVR (1.3%) and MIAVR (0.7%) experienced smaller rates. Incidence of stroke decreased in 2014 for all but TA-TAVR (Fig. 7) . SAVR (42%) and TF-TAVR (37%) had the largest proportion of patients with postoperative stroke, whereas MIAVR (12%) and TA-TAVR (9%) were smaller.
Atrial fibrillation
The greatest overall incidence of AF occurred in SAVR (31.7%) patients (Fig. 7) . MIAVR (21.5%) and TA-TAVR (18.5%) experienced more similar overall rates, while TF-TAVR (4.4%) had the lowest overall rate. The overall proportion of AF was highest in SAVR (53%), while smaller proportions belonged to MIAVR (30%), TA-TAVR (11%) and TF-TAVR (6%).
Length of hospital stay
The overall average (Fig. 7 ) length of hospital stay (LOS) was lowest for TF-TAVR (4.6 days), then MIAVR (7.3 days), SAVR (8.8 days) and TA-TAVR (9.2 days). All four procedures underwent decreases in LOS from 2011 through 2014. The breakdown by procedure of days in the hospital throughout the period was 42% (SAVR), 37% (TF-TAVR), 12% (MIAVR) and 9% (TA-TAVR).
DISCUSSION
We analyzed clinical trends among 2571 patients with severe AS undergoing TF, TA, MIAVR, or SAVR. We found that: (1) TF increased exponentially in volume, (2) MIAVR steadily increased in volume, (3) SAVR and TA increased modestly until 2013 when they down trended and (4) no particular procedure outperformed the others regarding all clinical outcomes measured (mortality, stroke, AF, LOS). Our analysis showed that TF is being used in clinical practice for higher risk patients, while MIAVR is increasingly used as an alternative for SAVR in intermediate and lower risk patients. The increased use of TAVR in clinical practice to treat high-risk patients compared to SAVR underscores a paradigm shift in the treatment of severe AS. Prior to TAVR introduction in the United States, up to 34% of symptomatic patients remained untreated [5] . The initial adoption of minimally invasive therapies like TAVR and MIAVR expanded the coverage of AVR to untreated patients. We found similar trends towards minimally invasive therapies in our study. While SAVR led total case volume, clearly, there was a movement towards minimally invasive therapies as TAVR and MIAVR experienced larger growth than SAVR. We witnessed the clinical adoption of less invasive therapies in our study with extensive growth in TF (+595%), TA (+177%) and MIAVR (+57%).
Total AVR caseload doubled from 2011 to 2014 in our study, mimicking similar trends in Europe and the United States that experienced overall AVR growth [5] [6] [7] [8] . Total AVR in Germany increased 900% from 2007 (8766 cases) to 2013 (88 573 cases), while AVR increased 59% in Eastern Denmark from 2007 (339 cases) to 2015 (539 cases) [7, 8] . Most of the AVR growth is 
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attributed to TAVR, with a lesser extent from MIAVR. TAVR cases in Germany grew an astounding 6250% over a 7-year period from 144 to 9147 cases [7] . While SAVR accounted for the majority of case volume in Denmark from 2007 to 2015, there was far greater growth ascribed to TAVR. Starting in 2007 with 2 cases, TAVR volume in Denmark increased 9700% to 196 cases in 2015. Simultaneously, SAVR maintained the high volume load but only grew 2% over the same period [8] . We experienced similar trends where SAVR accounted for the largest share of total cases, but underwent the smallest growth compared to TF, TA, or MIAVR.
Initial trials for TAVR were promising in high risk patients, ultimately leading to United States Food and Drug Administration approval for high-risk patients on November 2, 2011 [3, 9] . As expected, we found that TAVR was used frequently as an alternative to SAVR in this cohort. For high-risk patients with STS > 8%, TF and TA underwent exponential growth from 2011 to 2014. Both increased steadily to 2013 where TA then decreased 37% while TF increased 88%. Simultaneously, SAVR volume decreased by 50% in 2014. Between 2013 and 2014, we witnessed a paradigm shift in the treatment of AS at our institutions. At this inflection point, TA was less frequently used while TF replaced SAVR as the therapy of choice for high-risk patients. The downtrend of TA compared to TF has been observed in other studies [7, 8] , and more recent evidence has shown TA to be associated with worse outcomes [10] . Additionally, the drop in TA volume may be due to changes in delivery design of TAVR. TF sheaths became smaller over time; therefore there was less demand for TA.
The use of TF for higher risk patients was seen throughout our study. It was used frequently for patients on dialysis, age > _ 80, redo operations, EF <40, BMI >30. It is possible that SAVR in these high risk patients may be of historic interest as TF-TAVR and MIAVR adoption increase. Age was an important variable in choice of therapy. For older patients, TF was clearly the favoured therapy, as it was used four times as much as SAVR for age > _ 80. Similar trends worldwide favoured TF in older patients [11] . Younger patients more frequently underwent SAVR, although MIAVR (+32%) grew significantly from 2013 to 2014. Concurrently, SAVR dropped 3% during this same period, suggesting the evolution of MIAVR as an important modality in patients younger than 80 years.
For patients with prior cardiac surgery, TF was the preferred therapy in our study, used nearly five times as much as SAVR. Other studies have demonstrated related trends. In a metaanalysis by Tourmousoglou et al. [12] , TAVR was an acceptable alternative to SAVR in redo AVR for failed bioprosthetic valves for certain high-risk patients (1 year mortality: SAVR 76.1%, TAVR 83.2%). Similar to other variables in our study between 2013 and 2014, we saw an uptrend in MIAVR (+90%) while SAVR (-18%) and TA (-48%) decreased in the latter periods, suggesting a movement towards less invasive procedures in redo AVR. For most patients with prior cardiac surgery, the trend will likely favour TAVR for redo operations in any patient with prior cardiac surgery and it will likely be rare that we redo SAVR operations.
A similar theme for low EF and dialysis patients undergoing AVR for isolated AS during the inflection point from 2013 to 2014 continued in this study. TF and MIAVR had significant growth while SAVR decreased in volume, signifying a trend towards less invasive therapies for higher risk patients. While we have noticed an overall downtrend in TA during 2014 for several variables, it actually increased 33% for dialysis patients. When stratified by BMI, less invasive therapies again accounted for most of the growth. Overall, TF had the largest gains, followed by MIAVR, TA and then SAVR regardless of BMI <30 or BMI > _ 30. MIAVR and TF trended up at the inflection point, while MIAVR and surprisingly TA, were frequently used for BMI > _ 30.
We stratified each procedure by clinical outcomes (30-day mortality, stroke, AF, LOS) in an effort to provide a possible objective rationale for the volume changes throughout the study period. No one procedure was an obvious choice over the others based on all four clinical outcomes we measured. Looking at each outcome individually, we were surprised to find TF-TAVR experienced a large increase in 30-day mortality in 2014. It is unclear why there was a large uptrend in deaths in 2014, but it likely corresponds to study evidence showing that TF-TAVR patients were higher risk with increased comorbidities. TF-TAVR volume trended up in 2014 with regards to STS score >8%, age > _80 years, previous cardiac operation, dialysis, EF < 40 and BMI >30, therefore, patients may be more likely to suffer fatal outcomes. Similar to other studies, TA-TAVR expectedly had the highest incidence of death [13] . Interestingly, MIAVR experienced the smallest rate overall (0.6%). TF-TAVR and SAVR experienced the high rates of stroke from 2012 to 2013 before sharply declining in 2014. Historically, TAVR has been associated with greater risk of stroke [7] . According to the PARTNER 1 trial using first generation devices, stroke was more likely at 30 days for TAVR patients versus SAVR, although by 5 years the difference had diminished [3, 9] . More recent studies have demonstrated favourable outcomes in stroke for TAVR due, in part, to enhance technical expertise and device improvements [14] . While a multifactorial issue, our patients experienced a large drop in stroke for TAVR as we overcame the learning curve of the technique and switched to second generation devices with smaller sheath-delivery systems.
It is not completely apparent what contributed to the rise and fall of stroke in SAVR patients. The rise could be attributed to the uptrend in SAVR patients for the STS 4-8% risk pool. Therefore, higher risk patients underwent SAVR and were more likely to experience complications. The concurrent drop in 2014 was likely correlated to the higher number of SAVR patients having increased complications. This helped drive us to utilize MIAVR more frequently in carefully selected patients. From our study, MIAVR caseload increased for patients with STS <4% and STS 4-8% with concomitant drops in SAVR for the same risk groups. Despite the increased caseload over the study period, MIAVR maintained one of the lowest incidences of stroke (0.7%).
SAVR patients also experienced the highest incidence (31.7%) of atrial fibrillation (AF) throughout the study. The volume of cases with AF in 2013-2014 corresponds to decreased SAVR utilization during the same period with simultaneous increases in MIAVR (STS <4%, 4-8%) and TF-TAVR (STS >8%). Similar to stroke, MIAVR and TF-TAVR volume increased as it replaced SAVR in select patients.
All 4 procedures experienced progressive decline in LOS. TF-TAVR and MIAVR experienced the shortest LOS. The quicker LOS for TF-TAVR and MIAVR may have been a driver for increased adoption of these procedures over SAVR and TA-TAVR, although it is difficult to ascertain from the available data. Shorter hospital stays were reportedly cost-effective despite upfront costs for minimally invasive procedures, which could feasibly drive their clinical adoption [15] .
We have seen the widespread uptrend of TAVR for high-risk patients (STS >8%) both worldwide and in this study. What is less apparent is the application of MIAVR and TAVR for intermediate and lower risk patients. Minimally invasive therapies were less defined for these risk pools, and until very recently, TAVR was mainly accepted for high-risk patients. In this study, SAVR dominated overall case volume for intermediate risk patients (STS 4-8%) but actually trended down from 2012 to 2014 (-15%) while MIAVR and TF steadily increased all 4 years. It is unclear whether TF or MIAVR is preferred for intermediate-risk patients in this study, but there is a definite adoption of both procedures.
In 2016, Leon et al. [16] compared TAVR and SAVR in intermediate-risk patients in a randomized trial using the second generation SAPIEN XT valve (Edwards Lifesciences, Irvine, CA, USA) that found decreased mortality in patients who underwent TF-TAVR compared to SAVR at 2 years. Additional support in a propensity score analysis for intermediate patients undergoing TAVR by Thourani et al. [14] showed the superiority of TAVR using the third generation SAPIEN 3 valve (Edwards Lifesciences, Irvine, CA, USA) over SAVR based on favourable outcomes in mortality and stroke at 1 year for intermediate-risk patients. On 18 August 2016, the US FDA approved an expanded indication for the Sapien XT and Sapien 3 transcatheter heart valves for patients with AS who are at intermediate-risk for death with an STS score greater than 3% or complications associated with openheart surgery [17] . This current study period was prior to the FDA approval of TAVR for intermediate risk patients and we suspect that TF-TAVR will continue to increase in this patient cohort.
Also, the Medtronic CoreValve Surgical Replacement and Transcatheter Aortic Valve Implantation (SURTAVI) Trial is currently evaluating the minimally invasive CoreValve System in less sick patients who are typically treated with SAVR. SURTAVI trial is an ongoing multicentre trial comparing clinical outcomes for TAVR and SAVR in intermediate-risk patients defined by a STS risk score of 3-8%. Results of this study will further provide guidance on how to best address intermediate-risk patients, who along with their physicians are looking for less invasive options for treating AS [18] .
This study showed that SAVR and MIAVR competed each year for the highest volume for lower risk patients (STS <4%), although at the inflection point (2013-2014) we again saw trends towards minimally invasive therapies (MIAVR: +35%, SAVR: -8%). Current randomized trials are underway to evaluate TAVR's role in low-risk patients. The outcomes could have a significant impact on the role of minimally invasive therapies on treating AS, and, if successful, would likely uptrend the way of high-risk patients. TAVR is likely to gain further market share of total AVR as it covers more lower risk patients, highlighting the importance of this procedure for the future and the relevance of learning this technique.
While MIAVR has been used in practice longer than TAVR, it might have been the introduction of TAVR that highlighted minimally invasive therapies and helped drive its greater acceptance. Despite having evidence demonstrating several benefits prior to TAVR approval, MIAVR has not been widely used [19] . The recent growth trend for MIAVR suggests that it has likely benefitted from the halo effect of TAVR's acceptance in the mainstream. As we track the evolution of procedures in treating severe AS in our study, it appears that the dial has shifted in the direction of minimally invasive technologies. We believe that the results can be extrapolated in the 'real world' clinical practices given the increasing adoption of MIAVR and TAVR from small, medium and large volume centres. It is also important to note, however, that there exists a paucity of studies that compare TF-TAVR versus MIAVR in intermediate and low risk patients, thus emphasizing the importance of further investigation and maintaining equipoise when deciding on modalities.
Limitations
The current study does have some important limitations. The study was not designed to differentiate between specific valves used for TAVR, and we did not stratify by each type of device used. Multiple TAVR valves are available on the market; therefore, each valve has its own intrinsic complications, which could conceivably affect outcomes. Given the time course of the study, most of the TAVR valves were first-generation Edwards valves. This study was prior to the FDA approval of Sapien XT and Sapien 3 transcatheter heart valves in August 2016 for intermediate-risk patient populations with AS thus we expect results will likely continue to change possibly favouring TAVR growth trend in this subset of patients as well. Potential bias towards MIAVR may exist due to the increased familiarity with the procedure at our institutions, although a multidisciplinary heart team assisted in mitigating the bias. Finally, we acknowledge the caveat of extrapolating our results to other clinical practices worldwide.
CONCLUSIONS
Our results suggest that MIAVR and TAVR are already established as important alternatives to SAVR for patients with AS. The growth for these alternative techniques has already commenced and it is likely to continue. Both surgical techniques increased in volume over the study period, which is consistent with growth trends observed for both procedures globally.
As we witness the clinical adoption of minimally invasive techniques, it is clear that TAVR will be essential to the treatment of valvular heart disease in the upcoming years. This study and others have demonstrated the increasing relevance of MIAVR, consequently, there should be a strong impetus for surgeons to train and develop expertise in both approaches. As the demand for minimally invasive modalities increase, further studies comparing MIAVR versus TF-TAVR in low and intermediate risk patients are warranted.
